drugset / Trial / NCT06926673
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study will assess safety and pharmacokinetics and pharmacodynamics (PK/PD) of novel regimens (Dostarlimab plus belrestotug , and Dostarlimab plus belrestotug plus nelistotug) in participants with previously treated NSCLC.
Timeline
- Start
- 2021-12-23
- Primary completion
- 2024-05-02
- Completion
- 2024-05-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belrestotug | Monoclonal antibody | — | — |
| Subject | Dostarlimab | Monoclonal antibody | — | — |
| Subject | Nelistotug | Monoclonal antibody | — | — |